Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Weill Medical College of Cornell University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01799278CT.gov A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Small Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alisertib (this asset) | Weill Medical College of Cornell University | P2 | B · 57 |
| Carboplatin | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Fred Hutchinson Cancer Center | P2 | B |
| Pembrolizumab | Rahul Aggarwal | P2 | B |
| Cabazitaxel | M.D. Anderson Cancer Center | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Oxodotreotide | National Cancer Institute (NCI) | P2 | CCC |
| Abiraterone | University of Washington | P2 | CCC |
| Bet Bromodomain Inhibitor Zen-3694 | Rahul Aggarwal | P2 | CCC |
+14 more in the Prostate Small Cell Carcinoma cohort
Other indications for Alisertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P2 | BB · 71 |
| Mantle Cell Lymphoma | — | P2 | BB · 69 |
| Follicular Lymphoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alisertib in Prostate Small Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/alisertib-prostate-small-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →